These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27659966)

  • 1. Altered glutamate release in the dorsal striatum of the MitoPark mouse model of Parkinson's disease.
    Farrand AQ; Gregory RA; Bäckman CM; Helke KL; Boger HA
    Brain Res; 2016 Nov; 1651():88-94. PubMed ID: 27659966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.
    Langley MR; Ghaisas S; Ay M; Luo J; Palanisamy BN; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2018 Jan; 64():240-255. PubMed ID: 28595911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
    Shan L; Diaz O; Zhang Y; Ladenheim B; Cadet JL; Chiang YH; Olson L; Hoffer BJ; Bäckman CM
    Brain Res; 2015 Aug; 1618():261-9. PubMed ID: 26086365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
    Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
    Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK; Keyghobadi M; Moore C; Meshul CK
    Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.
    Beckstead MJ; Howell RD
    Exp Neurol; 2021 Jul; 341():113707. PubMed ID: 33753138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of systemic administration of iptakalim on extracellular neurotransmitter levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats.
    Wang S; Hu LF; Zhang Y; Sun T; Sun YH; Liu SY; Ding JH; Wu J; Hu G
    Neuropsychopharmacology; 2006 May; 31(5):933-40. PubMed ID: 16123757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
    Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
    Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Release parameters during progressive degeneration of dopamine neurons in a mouse model reveal earlier impairment of spontaneous than forced behaviors.
    Chen YH; Hsieh TH; Kuo TT; Kao JH; Ma KH; Huang EY; Chou YC; Olson L; Hoffer BJ
    J Neurochem; 2019 Jul; 150(1):56-73. PubMed ID: 30933310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.
    Dervan AG; Meshul CK; Beales M; McBean GJ; Moore C; Totterdell S; Snyder AK; Meredith GE
    Exp Neurol; 2004 Nov; 190(1):145-56. PubMed ID: 15473988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.
    Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL
    J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease.
    Divito CB; Steece-Collier K; Case DT; Williams SP; Stancati JA; Zhi L; Rubio ME; Sortwell CE; Collier TJ; Sulzer D; Edwards RH; Zhang H; Seal RP
    J Neurosci; 2015 Nov; 35(45):14983-99. PubMed ID: 26558771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson's disease.
    Wang M; Zhu J; Pan Y; Dong J; Zhang L; Zhang X; Zhang L
    J Neurosci Res; 2015 Mar; 93(3):487-94. PubMed ID: 25388401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
    Ekstrand MI; Galter D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S185-8. PubMed ID: 20082987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice.
    Farrand AQ; Gregory RA; Scofield MD; Helke KL; Boger HA
    Neurobiol Aging; 2015 Mar; 36(3):1569-76. PubMed ID: 25577412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease.
    Good CH; Hoffman AF; Hoffer BJ; Chefer VI; Shippenberg TS; Bäckman CM; Larsson NG; Olson L; Gellhaar S; Galter D; Lupica CR
    FASEB J; 2011 Apr; 25(4):1333-44. PubMed ID: 21233488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.